All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Acute Myeloid Leukemia: investigating the clinical significance of γ-catenin

By Cynthia Umukoro

Share:

Jul 20, 2016


Xu et al. from Nanjing Medicine University compared γ-catenin mRNA levels in bone marrow mononuclear cells between naïve primary Acute Myeloid Leukemia (AML) patients and healthy donors. The function of γ-catenin in the pathogenesis of AML was also investigated. The findings of this study were published in Onco Targets Ther in June 2016.

The data showed that γ-catenin mRNA expression levels were significantly higher in AML patients than in healthy donors. Furthermore, patients who had achieved Complete Remission (CR) in one to two cycles had significantly lower γ-catenin mRNA expression levels in comparison to refractory patients with slow responses.

Consequently, clarifying the role of γ-catenin in AML could serve to increase the understanding of the pathological mechanism of the disease in addition to aiding the development a potential biomarker for clinical diagnosis and prognosis.

Abstract

Dysregulation of γ-catenin may function as an oncogenic factor in various malignancies. We investigated γ-catenin expression in acute myeloid leukemia (AML) and explored its role in the pathogenesis of AML. γ-Catenin was significantly overexpressed in AML patients compared to healthy donors.

01.jpg

The γ -catenin expression in AML patients with lower white blood cells (<30×109/L) was significantly higher than those with higher white blood cells (≥30×109/L). The expression levels of γ-catenin in AML patients with mutated CEBPα were significantly higher than those with unmutated CEBPα. AML patients with lower γ-catenin levels were more likely to achieve complete remission compared with patients who have higher γ-catenin levels. In K562 cells, γ-catenin knockdown suppressed cellular proliferation, while the cellular migration was greatly enhanced. Moreover, knocking down of γ-catenin enhanced the cytotoxicity of decitabine in K562 cells. Our investigation has indicated a potential role of γ-catenin in the pathogenesis of AML.

References